Table 1 Pharmacokinetics, drug-likeness of top FDA-approved drugs with PDK3.
ADME study of molecule | Features | Bagrosin | Dehydrocholic acid |
---|---|---|---|
Canonical smiles | CC1(C(=O)NC(=O)N1)C2=CC3=C(C=CC4=CC=CC=C43)C=C2 | CC(CCC( O)O)C1CCC2C1(C(=O)CC3C2C(=O)CC4C3(CCC(=O)C4)C)C | |
Molecular formula | C18H14N2O2 | C24H34O5 | |
Structure | |||
Physiochemical properties | Molecular weight | 290.32 g/mol | 402.52 g/mol |
Number of heavy atoms | 22 | 29 | |
Number of aromatic heavy atoms | 14 | 0 | |
Fraction Csp3 | 0.11 | 0.83 | |
Number of rotatable bonds | 1 | 4 | |
Number of H-bond acceptors | 2 | 5 | |
Number of H-bond donors | 2 | 1 | |
Molar refractivity | 92.83 | 110.88 | |
Topological polar surface area (TPSA) | 58.20 Å2 | 88.51 Å2 | |
Lipophilicity | Log Po/w (iLOGP) | 1.93 | 2.27 |
Log Po/w (XLOGP3) | 3.52 | 2.56 | |
Log Po/w (WLOGP) | 2.18 | 4.07 | |
Log Po/w (MLOGP) | 2.59 | 2.75 | |
LogPo/w(SILICOS-IT) | 3.38 | 4.29 | |
Consensus Log Po/w | 2.72 | 3.19 | |
Water solubility | Log S (ESOL) | − 4.26, Moderately soluble | − 3.68, Soluble |
Log S (Ali) | − 4.43,Moderately Soluble | − 4.07, Moderately Soluble | |
Log S (SILICOS-IT) | − 6.83,Poorly Soluble | − 4.40, Moderately Soluble | |
Pharma | GI absorption | High | High |
cokinetics | BBB permeant | Yes | No |
P-gp substrate | Yes | Yes | |
CYP1A2 inhibitor | Yes | No | |
CYP2C19 inhibitor | Yes | No | |
CYP2C9 inhibitor | Yes | No | |
CYP2D6 inhibitor | Yes | No | |
CYP3A4 inhibitor | No | No | |
LogKp (skin permeation) | − 5.57 cm/s | − 6.94 cm/s | |
Drug likeliness | Lipinski | Yes | Yes |
Ghose | Yes | Yes | |
Veber | Yes | Yes | |
Egan | Yes | Yes | |
Muegge | Yes | Yes | |
Bioavailability Score | 0.55 | 0.56 | |
Medicin | PAINS | 0 alert | 0 alert |
al chemistry | Brenk | 2 alerts: hydantoin,polycyclic_aromatic_hydrocarbon_3 | 0 alert |
Leadlikeness | No; 1 violation: XLOGP3 > 3.5 | No; 1 violation: MW > 350 | |
Syntheticaccessibility | 2.34 | 4.53 |